share_log

On Thursday, Alchemab Therapeutics Entered A Collaboration With Eli Lilly To Discover, Develop, And Commercialize Up To Five Therapeutics For Amyotrophic Lateral Sclerosis; Alchemab Will Receive An Undisclosed Upfront Payment And Is Eligible To...

Benzinga ·  Jan 10 19:19

On Thursday, Alchemab Therapeutics Entered A Collaboration With Eli Lilly To Discover, Develop, And Commercialize Up To Five Therapeutics For Amyotrophic Lateral Sclerosis; Alchemab Will Receive An Undisclosed Upfront Payment And Is Eligible To Receive Milestone Payments, Plus Royalties

Alchemab's technology platform uses patient samples from individuals with unusually slow rates of disease progression to identify antibodies associated with resilience.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment